P7C3-A20

Last updated
P7C3-A20
P7C3-A20.svg
Names
IUPAC name
N-[3-(3,6-Dibromocarbazol-9-yl)-2-fluoropropyl]-3-methoxyaniline
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
PubChem CID
  • InChI=1S/C22H19Br2FN2O/c1-28-18-4-2-3-17(11-18)26-12-16(25)13-27-21-7-5-14(23)9-19(21)20-10-15(24)6-8-22(20)27/h2-11,16,26H,12-13H2,1H3
    Key: XNLTWMQBJFWQOU-UHFFFAOYSA-N
  • COC1=CC=CC(=C1)NCC(CN2C3=C(C=C(C=C3)Br)C4=C2C=CC(=C4)Br)F
Properties
C22H19Br2FN2O
Molar mass 506.213 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

P7C3-A20 is a synthetic chemical compound belonging to the carbazole class. It was developed as a more potent analog of P7C3. It functions as an activator of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the NAD+ salvage pathway. [1] P7C3-A20 exhibits proneurogenic and neuroprotective properties in preclinical models, crossing the blood-brain barrier and demonstrating efficacy in various models of brain injury and neurodegeneration. Research has investigated its potential to treat Alzheimer's disease, where it reversed pathological features and restored cognitive function in mice. [1] As of 2025, P7C3-A20 remains an experimental compound with no established clinical use in humans.

Contents

Mechanism of action

P7C3-A20 acts as a small-molecule activator of NAMPT, enhancing the conversion of nicotinamide to nicotinamide mononucleotide (NMN), a precursor to NAD+. This increases intracellular NAD+ levels, supporting cellular energy metabolism, mitochondrial function, and resistance to stress-induced cell death. [1] Additional pathways reported in models include activation of PI3K/AKT/GSK3β signaling and restoration of NAD+ homeostasis without elevating NAD+ to supraphysiologic levels. [2]

Research

P7C3-A20 has shown efficacy in preclinical animal models, including:

References

  1. 1 2 3 4 Chaubey, Kalyani; et al. (2025). "Pharmacologic reversal of advanced Alzheimer's disease in mice and identification of potential therapeutic nodes in human brain". Cell Reports Medicine 102535. doi:10.1016/j.xcrm.2025.102535. PMID   41435831.
  2. 1 2 Bai, Junjie; Zeng, Shanshan; Zhu, Jinjin; Fu, Changchang; He, Minzhi; Zhu, Jianghu; Chen, Shangqing; Fu, Xiaoqin; Li, Peijun; Lin, Zhenlang (2020). "The Small Molecule P7C3-A20 Exerts Neuroprotective Effects in a Hypoxic–ischemic Encephalopathy Model via Activation of PI3K/AKT/GSK3β Signaling". Neuroscience. 441: 197–208. doi:10.1016/j.neuroscience.2020.05.051. PMID   32504794.
  3. Vázquez-Rosa, Edwin; Shin, Min-Kyoo; Dhar, Matasha; Chaubey, Kalyani; Cintrón-Pérez, Coral J.; Tang, Xinmiao; Liao, Xudong; Miller, Emiko; Koh, Yeojung; Barker, Sarah; Franke, Kathryn; Crosby, Danyel R.; Schroeder, Rachel; Emery, Josie; Yin, Terry C.; Fujioka, Hisashi; Reynolds, James D.; Harper, Matthew M.; Jain, Mukesh K.; Pieper, Andrew A. (2020). "P7C3-A20 treatment one year after TBI in mice repairs the blood–brain barrier, arrests chronic neurodegeneration, and restores cognition". Proceedings of the National Academy of Sciences. 117 (44): 27667–27675. Bibcode:2020PNAS..11727667V. doi: 10.1073/pnas.2010430117 . PMC   7959512 . PMID   33087571.
  4. Yang, Zhiqing; Wang, Zhenchao; Deng, Xiaoqi; Zhu, Lingxin; Song, Zhaomeng; Cao, Changyu; Li, Xinran (2024). "P7C3-A20 treats traumatic brain injury in rats by inhibiting excessive autophagy and apoptosis". Neural Regeneration Research. 19 (5): 1078–1083. doi: 10.4103/1673-5374.380910 . PMC   10749631 . PMID   37862211.
  5. "Scientists reverse Alzheimer's in mice and restore memory". sciencedaily.com. December 24, 2025.
  6. Wang, Shu-Na; Xu, Tian-Ying; Wang, Xia; Guan, Yun-Feng; Zhang, Sai-Long; Wang, Pei; Miao, Chao-Yu (2016). "Neuroprotective Efficacy of an Aminopropyl Carbazole Derivative P7C3-A20 in Ischemic Stroke". CNS Neuroscience & Therapeutics. 22 (9): 782–788. doi:10.1111/cns.12576. PMC   6492790 . PMID   27333812.